Vaccine and Vaccination Practice Questions

Q: Live influenza vaccine is given by which route?

Intranasal. ***Intranasal*** - The **live attenuated influenza vaccine (LAIV)** is specifically designed for **intranasal administration**, allowing it to mimic natural infection in the respiratory tract. - This route promotes a robust **mucosal immune response**, which is crucial for respiratory pathogens. *Intradermal* - **Intradermal vaccines** are typically administered into the dermis, beneath the epidermis. - While some influenza vaccines (e.g., Fluzone Intradermal) exist, the **live influenza vaccine** is not given via this route. *Subcutaneous* - **Subcutaneous injection** delivers the vaccine into the fatty tissue just under the skin. - While some vaccines are given subcutaneously, the **live attenuated influenza vaccine** is not. *Intramuscular* - Most **inactivated influenza vaccines** are administered intramuscularly, depositing the vaccine into muscle tissue. - The **live attenuated influenza vaccine** is not given via this route as it is designed to replicate in the upper respiratory tract.

Q: What is the role of magnesium [Mg] in the Inactivated Polio Vaccine (IPV)?

Stabilizer. ***Stabilizer*** - Magnesium (Mg) is included in IPV formulations primarily to **maintain the integrity and potency** of the viral antigens. - It helps prevent the **degradation of the inactivated poliovirus** particles, ensuring a consistent immune response upon vaccination. *Adjuvant* - Adjuvants are substances that **enhance the immune response** to an antigen, often by creating a depot effect or stimulating immune cells. - While essential in some vaccines, magnesium's role in IPV is not primarily to boost immunogenicity but to protect the antigen itself. *Preservative* - Preservatives are added to multi-dose vaccine vials to **prevent microbial contamination** after the vial has been opened. - Common preservatives include 2-phenoxyethanol or thimerosal (though less frequently used now), which have antimicrobial properties not shared by magnesium. *Antiinfective* - An antiinfective agent's primary function is to **kill or inhibit the growth of infectious microorganisms**. - Magnesium does not possess significant antiinfective properties at the concentrations used in vaccines and is not intended to treat or prevent infections in this context.

Q: Rota-teq oral vaccine for rotavirus contains how many reassorted rotaviruses?

5 reassorted rotaviruses. ***5 reassorted rotaviruses*** - **RotaTeq** (RV5) is a pentavalent vaccine containing **five live attenuated human-bovine reassortant rotaviruses**. - These reassortants express four different G serotypes (G1, G2, G3, G4) and one P serotype (P1A[8]), providing broad protection against common rotavirus strains causing severe gastroenteritis. *2 reassorted rotaviruses* - This option is incorrect as **RotaTeq** contains five reassorted rotaviruses, not two. - The number two is not associated with any of the currently available rotavirus vaccines. *3 reassorted rotaviruses* - This option is incorrect. **RotaTeq** does not contain three reassorted rotaviruses. - No major rotavirus vaccine contains exactly three reassorted strains. *4 reassorted rotaviruses* - This option is incorrect. **RotaTeq** specifically contains five reassorted rotaviruses, not four. - While other rotavirus vaccines exist (e.g., Rotarix is monovalent), none are based on four reassorted strains.

Q: Meningococcal polysaccharide vaccine (MPSV4) contains?

50 mcg of polysaccharide of each strain. ***50 mcg of polysaccharide of each strain*** - The **polysaccharide meningococcal vaccine (MPSV4)** contains **50 mcg** of purified capsular polysaccharide from each of the four serogroups (A, C, W-135, and Y). - This specific dosage ensures an adequate immune response without causing excessive reactogenicity. *100 mcg of polysaccharide of each strain* - This dosage is **higher** than the standard concentration found in MPSV4 and is not the correct amount per strain. - Using a higher concentration could potentially increase adverse reactions without significantly enhancing immunogenicity. *1000 mcg of polysaccharide of each strain* - This amount is **significantly higher** than the immunologically effective dose for meningococcal polysaccharides. - Such a high dose would be economically unfeasible and likely lead to higher rates of side effects. *5000 mcg of polysaccharide of each strain* - This is an **extremely high** and impractical dosage for a vaccine. - It would be associated with a high risk of adverse events and would not be used in vaccine formulations.

Q: What is the specific protein content of the malaria vaccine RTS,S/AS01?

Sporozoite protein (Circumsporozoite protein). ***Sporozoite protein*** - The RTS,S/AS01 vaccine specifically targets the **circumsporozoite protein (CSP)** from the *Plasmodium falciparum* sporozoite stage. - This design aims to prevent **malaria infection** by blocking the parasite before it can infect liver cells. *Gametocytic protein* - Vaccines targeting gametocytic proteins are in development but are designed to block **transmission** of malaria, not prevent initial infection. - They aim to induce antibodies that neutralize gametes within the mosquito, preventing the parasite's sexual reproduction. *Polysaccharide sheath* - **Polysaccharide components** are common in bacterial vaccines (e.g., pneumococcal), but not the primary immunogen in RTS,S, which is a protein-based vaccine. - *Plasmodium* parasites do not possess a significant polysaccharide sheath that serves as a primary vaccine target in this context. *Lipoprotein envelope* - **Lipoprotein envelopes** are characteristic of some viruses (e.g., influenza, HIV), not typically the primary antigen of interest for *Plasmodium falciparum* sporozoites. - While there are lipid components in the parasite, the specific targeted antigen for RTS,S is a **protein**.

Q: Which of the following vaccines is most likely to cause adverse effects in individuals with egg allergies?

Influenza vaccine. ***Influenza vaccine*** - Historically and currently, **most influenza vaccines are manufactured using embryonated chicken eggs**, which introduces egg proteins into the vaccine - While modern influenza vaccines contain **very small amounts of ovalbumin** (egg protein), they remain the vaccine **most likely to cause concerns** in individuals with egg allergies among the options listed - Current CDC and ACIP guidelines state that individuals with egg allergy can receive influenza vaccine without special precautions, but it is still the vaccine with **historical egg allergy associations** - Some egg-free recombinant and cell-based influenza vaccines are now available for those with severe egg allergies *Hepatitis B vaccine* - The **Hepatitis B vaccine is produced using recombinant DNA technology** in yeast cells (Saccharomyces cerevisiae) - It contains **no egg proteins whatsoever** and is completely safe for individuals with egg allergies - There is no biological basis for egg allergy concerns with this vaccine *Pneumococcal vaccine* - Both **pneumococcal polysaccharide (PPSV23) and conjugate (PCV13/PCV15/PCV20) vaccines** are manufactured using bacterial culture systems - They contain **no egg proteins** and pose no risk to individuals with egg allergies - Safe for all egg-allergic individuals without any precautions *Meningococcal vaccine* - **Meningococcal vaccines** (both conjugate and polysaccharide forms) are produced using bacterial components - Manufacturing process **does not involve eggs or egg products** - Completely safe for individuals with egg allergies

Q: What is the serum marker after Hepatitis B vaccination?

Anti-HBs. **Anti-HBs** - The Hepatitis B vaccine contains **HBsAg** (Hepatitis B surface antigen), which stimulates the immune system to produce **antibodies against HBsAg (Anti-HBs)**. - The presence of **Anti-HBs** indicates successful vaccination and immunity to Hepatitis B infection. *Anti-HBe* - **Anti-HBe** antibodies develop during an acute or chronic Hepatitis B infection and indicate a decrease in viral replication and infectivity. - This marker is not associated with vaccination. *Anti-HBc* - **Anti-HBc** (antibodies against Hepatitis B core antigen) is produced during an active or past Hepatitis B infection, but not as a result of vaccination. - It signifies exposure to the **core protein** of the virus. *HBs antigen* - **HBs antigen (HBsAg)** is a surface protein of the Hepatitis B virus that indicates active acute or chronic infection. - It is the antigen used in the vaccine to stimulate an immune response, but it is not a marker of immunity after vaccination.

Q: What is the Hib conjugate vaccine made of?

Capsular polysaccharide with carrier. ***Capsular polysaccharide with carrier*** - The Hib conjugate vaccine uses a **polysaccharide capsule** from *Haemophilus influenzae* type b (Hib) covalently linked to a **protein carrier** [1]. - This conjugation allows activated B cells to present the polysaccharide to T helper cells, inducing a strong **T-cell dependent immune response** and **immunological memory**, especially in infants [1]. *Capsular polysaccharide* - A vaccine made only of **capsular polysaccharide** would be a **polysaccharide vaccine**, which induces a **T-cell independent immune response**. - This type of vaccine is **poorly immunogenic in infants** and does not generate long-lasting memory. *Purified protein with carrier* - This describes components of some **protein subunit vaccines**, but not specifically the Hib vaccine, which targets the polysaccharide capsule. - While it employs a carrier protein, the primary antigen is the **polysaccharide**, not a purified bacterial protein. *Cell wall polysaccharide* - The Hib vaccine specifically targets the **capsular polysaccharide**, which is distinct from the general cell wall polysaccharides found in the bacterial outer membrane. - The **capsule** is the primary virulence factor and target for protective immunity in Hib.

Q: Which statement is true regarding the influenza vaccine?

All statements are correct.. ***All statements are correct.*** - Each of the preceding statements is factually accurate regarding influenza vaccines. - The **inactivated vaccine** is widely used, the **live attenuated vaccine** is administered via nasal spray, and the **inactivated vaccine** is given intramuscularly [1]. *The inactivated vaccine is used most commonly.* - The **inactivated influenza vaccine (IIV)**, given by injection, is the most frequently administered type of influenza vaccine. - It is recommended for most age groups and is safe for individuals with chronic medical conditions, pregnant women, and the elderly. *The live attenuated vaccine is given by nasal spray.* - The **live attenuated influenza vaccine (LAIV)**, also known as FluMist, is administered as a **nasal spray** [1]. - This vaccine is suitable for healthy individuals aged 2-49 years and is not recommended for pregnant women or individuals with certain immune compromising conditions. *The inactivated vaccine is given intramuscularly in the deltoid.* - The standard route of administration for the **inactivated influenza vaccine (IIV)** is via **intramuscular injection**, most commonly into the **deltoid muscle** in adults and older children [1]. - This method ensures proper absorption and an effective immune response, a common practice for many vaccines.

Q: Capsular polysaccharide derived vaccine is available for all meningococci except?

Group B. ***Group B*** - The capsular polysaccharide of **Group B meningococci** is composed of **polysialic acid**, which is poorly immunogenic in humans because it structurally mimics human neural cell adhesion molecules. - Due to its **poor immunogenicity** and risk of autoantibody production, traditional polysaccharide vaccines are ineffective against Group B. *Group A* - Polysaccharide vaccines for **Group A meningococci** (e.g., in Menactra, Menveo) are effective in inducing a protective immune response. - Group A is a major cause of meningococcal disease, particularly in the **"meningitis belt"** of sub-Saharan Africa. *Group C* - **Capsular polysaccharide vaccines** are available and effective against Group C meningococcal disease, often included in quadrivalent formulations. - These vaccines elicit a robust **antibody response** against the Group C polysaccharide. *Group Y* - Vaccines containing the **capsular polysaccharide** of Group Y meningococci are effective and commonly included in quadrivalent vaccines. - Group Y is a significant cause of meningococcal disease, particularly in **North America and Europe**.

Question 1

Live influenza vaccine is given by which route?

Accepted Answer

Intranasal

Answer

Intradermal

Answer

Subcutaneous

Answer

Intramuscular

Question 2

What is the role of magnesium [Mg] in the Inactivated Polio Vaccine (IPV)?

Accepted Answer

Stabilizer

Answer

Adjuvant

Answer

Preservative

Answer

Antiinfective

Question 3

Rota-teq oral vaccine for rotavirus contains how many reassorted rotaviruses?

Accepted Answer

5 reassorted rotaviruses

Answer

3 reassorted rotaviruses

Answer

4 reassorted rotaviruses

Answer

2 reassorted rotaviruses

Question 4

Meningococcal polysaccharide vaccine (MPSV4) contains?

Accepted Answer

50 mcg of polysaccharide of each strain

Answer

100 mcg of polysaccharide of each strain

Answer

1000 mcg of polysaccharide of each strain

Answer

5000 mcg of polysaccharide of each strain

Question 5

What is the specific protein content of the malaria vaccine RTS,S/AS01?

Accepted Answer

Sporozoite protein (Circumsporozoite protein)

Answer

Gametocytic protein

Answer

Polysaccharide sheath

Answer

Lipoprotein envelope

Question 6

Which of the following vaccines is most likely to cause adverse effects in individuals with egg allergies?

Accepted Answer

Influenza vaccine

Answer

Meningococcal vaccine

Answer

Hepatitis B vaccine

Answer

Pneumococcal vaccine

Question 7

What is the serum marker after Hepatitis B vaccination?

Accepted Answer

Anti-HBs

Answer

Anti-HBe

Answer

Anti-HBc

Answer

HBs antigen

Question 8

What is the Hib conjugate vaccine made of?

Accepted Answer

Capsular polysaccharide with carrier

Answer

Capsular polysaccharide

Answer

Purified protein with carrier

Answer

Cell wall polysaccharide

Question 9

Which statement is true regarding the influenza vaccine?

Accepted Answer

All statements are correct.

Answer

The live attenuated vaccine is given by nasal spray.

Answer

The inactivated vaccine is used most commonly.

Answer

The inactivated vaccine is given intramuscularly in the deltoid.

Question 10

Capsular polysaccharide derived vaccine is available for all meningococci except?

Accepted Answer

Group B

Answer

Group C

Answer

Group Y

Answer

Group A

Vaccine and Vaccination — MCQs

Vaccine and Vaccination — MCQs

On this page

Practice by Chapter

Want unlimited practice?